Patients' view of pharma slips but some firms gain ground on focused products
This article was originally published in Scrip
Executive Summary
Multinational pharmaceutical companies aren't the most disrespected segment of the health care industry; that dubious distinction went to for-profit health insurers in a late 2012 survey of 600 patient groups conducted by the independent UK-based research and consulting firm PatientView.